In vivo proof of concept for Anticalins®

24-Jan-2005

PIERIS Proteolab AG announced that one of its lead development candidates, Digical, completely neutralized lethal toxicity caused by an overdose of the cardiac steroid digoxin in a preclinical study. The dose of this Anticalin® was only approximately half the recommended dose of a marketed polyclonal antibody fragment product approved for the same purpose.

Recently, PIERIS has generated lipocalin muteins named Anticalins® against more than half a dozen protein targets with very high affinity and specificity. Now, the company has demonstrated therapeutic efficacy in a relevant preclinical model. This underlines the company's ability to generate development candidates from its proprietary Anticalin® technology platform. These Anticalins® are able to compete with antibodies.

Other news from the department research and development

More news from our other portals

So close that even
molecules turn red...

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous